mass confirmation is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-15. Numbers and descriptions here follow the published literature rather than marketing material.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Typical form for short synthetic peptides |
| Solubility class | Freely soluble in water and aqueous buffer | Dissolution aided by gentle mixing, not vigorous shaking |
| Typical storage temperature | −20 °C, desiccated | −80 °C used for long-term holding |
| Common analytical method | Reverse-phase HPLC with UV detection near 214 nm | Identity confirmed separately by mass spectrometry |
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming varies between suppliers and publications |
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Amivantamab, sold under the brand name Rybrevant, is a bispecific monoclonal antibody used to treat non-small cell lung cancer. Amivantamab is a bispecific epidermal growth factor (EGF) receptor-directed and MET receptor-directed antibody. It is the first treatment for adults with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The most common side effects include rash, infusion-related reactions, skin infections around the fingernails or toenails, muscle and joint pain, shortness of breath, nausea, fatigue, swelling in the lower legs or hands or face, sores in the mouth, cough, constipation, vomiting and changes in certain blood tests. Amivantamab was approved for medical use in the United States in May 2021, and in the European Union in December 2021. The US Food and Drug Administration considers it to be a first-in-class medication.
Analysis of CRISPR sequences revealed coevolution of host and viral genomes. The basic model of CRISPR evolution is newly incorporated spacers driving phages to mutate their genomes to avoid the bacterial immune response, creating diversity in both the phage and host populations. To resist a phage infection, the sequence of the CRISPR spacer must correspond perfectly to the sequence of the target phage gene. Phages can continue to infect their hosts' given point mutations in the spacer. Similar stringency is required in PAM or the bacterial strain remains phage sensitive.
The T5 exonuclease chews back DNA from the 5' end of each fragment, exposing 3' overhangs on each DNA fragment. The complementary overhangs on adjacent DNA fragments anneal via complementary base pairing. The Phusion DNA polymerase fills in any gaps where the fragments anneal. Taq DNA ligase repairs the nicks on both DNA strands. Because the T5 exonuclease is heat labile, it is inactivated at 50 °C after the initial chew back step. The product is thus stable, and the fragments assembled in the desired order. This one-pot protocol can assemble up to 5 different fragments accurately, while several commercial providers have kits to accurately assemble up to 15 different fragments in a two-step reaction. However, while the Gibson assembly protocol is fast and uses relatively few reagents, it requires bespoke DNA synthesis as each fragment has to be designed to contain overlapping sequences with the adjacent fragments and amplified via PCR. This reliance on PCR may also affect the fidelity of the reaction when long fragments, fragments with high GC content or repeat sequences are used.
==== Solders ==== Bismuth is utilised in silver-free electronic solders to provide solid solution strengthening. Because bismuth atoms are larger than tin atoms, their insertion into the tin crystal lattice distorts the structure and restricts the movement of crystal defects (dislocations). This atomic lattice distortion provides resistance to mechanical deformation during thermal cycling. Keeping the bismuth content below the solid solubility limit prevents microstructural instability and electromigration across the typical operating temperature range of electronic circuitry. Unlike particle-strengthened alloys (such as SAC305), this solid solution mechanism resists deformation without generating the dislocation pile-ups that drive microstructural recrystallisation, reducing a primary cause of joint failure and loss of electrical continuity.
Sources: en.wikipedia.org
== Origin == Missense mutations may be inherited or arise spontaneously, termed de novo mutations. Well studied diseases arising from inherited missense mutations include sickle cell anemia, cystic fibrosis, and early-onset Alzheimer's and Parkinson's disease. De novo mutations that increase or decrease the activity of synapses have been implicated in the development of neurological and developmental disorders, such a Autism Spectrum Disorder and intellectual delay.
As carbon dioxide concentrations rise, the rate at which sugars are made by the light-independent reactions increases until limited by other factors. RuBisCO, the enzyme that captures carbon dioxide in the light-independent reactions, has a binding affinity for both carbon dioxide and oxygen. When the concentration of carbon dioxide is high, RuBisCO will fix carbon dioxide. However, if the carbon dioxide concentration is low, RuBisCO will bind oxygen instead of carbon dioxide. This process, called photorespiration, uses energy, but does not produce sugars. RuBisCO oxygenase activity is disadvantageous to plants for several reasons:
The old "Same Olds" nickname fell into disuse, and by 1922 the other nicknames "Sash Wearers" and "Essendonians" that had been variously used from time to time were also abandoned. The team became universally known as "the Dons" (from EssenDON). (The club adopted the nickname "the Bombers" at the start of 1940 during the early phases of World War II, due to Windy Hill's proximity to what was then Melbourne’s main airport, Essendon Aerodrome.) In the 1922 season, playing in Essendon for the first time in decades, Essendon reached the final four for the first time since 1912, finishing in third place. In the 1923 season, the club topped the ladder with 13 wins from 16 games. After a 17-point Second Semi-Final loss to South Melbourne, Essendon defeated Fitzroy (who had beaten South Melbourne) in the 1923 Grand Final (then known as a "Challenge Final" due to its different finals format): Essendon 8.15 (63) to Fitzroy 6.10 (46). Amongst Essendon's best players were half-forward flanker George "Tich" Shorten, centre half-forward Justin McCarthy, centre half-back Tom Fitzmaurice, rover Frank Maher, and wingman Jack Garden. This was one of Essendon's most famous sides, dubbed the "Mosquito Fleet" due to the number of small, very fast players in the side. Six players were 5'6" (167 cm) or shorter.
Considering outright legalization of recreational drugs, New York Times columnist Eduardo Porter noted: Jeffrey Miron, an economist at Harvard who studies drug policy closely, has suggested that legalizing all illicit drugs would produce net benefits to the United States of some $65 billion a year, mostly by cutting public spending on enforcement as well as through reduced crime and corruption. A study by analysts at the RAND Corporation, a California research organization, suggested that if marijuana were legalized in California and the drug spilled from there to other states, Mexican drug cartels would lose about a fifth of their annual income of some $6.5 billion from illegal exports to the United States. In 2007, "An Open Letter to the President, Congress, Governors, and State Legislatures" signed by over 550 economists, including Nobel Laureates Milton Friedman, George Akerlof and Vernon L. Smith, endorsed the findings of a 2006 paper, "The Budgetary Implications of Marijuana Prohibition", by Harvard economist Jeffrey A. Miron. Comparing the cost of prohibition to the tax revenue if cannabis was taxed as regular consumer good, or similarly to alcohol, the letter stated that the budgetary impact, considered alongside evidence that "suggests prohibition has minimal benefits and may itself cause substantial harm", favors "a regime in which marijuana is legal but taxed and regulated like other goods".
=== Paul trap === A Paul trap (also known as a quadrupole ion trap) uses static direct current (DC) and radio frequency (RF) oscillating electric fields to trap ions. Paul traps are commonly used as components of mass spectrometers. Wolfgang Paul invented the Paul trap, hence its name. For this work he shared the 1989 Nobel Prize in Physics.
Sources: en.wikipedia.org
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.
Not necessarily. Some vendors use the name for the full 43-residue protein, while others apply it to a short actin-binding fragment or to a related tetrapeptide. The sequence should be confirmed from documentation rather than assumed from the label.
No thymosin beta-4 fragment holds marketing approval as a medicine in major jurisdictions. Material offered for sale is typically labelled for laboratory research only.
The lyophilised powder is typically held at -20 C or lower in a dry, dark place. Reconstituted solutions are aliquoted and frozen to avoid repeated freeze-thaw cycles.